HomeBUSINESS
BUSINESS

Takeda’s Oral Relugolix Scores Non-Inferiority vs Leuprorelin in Uterine Fibroids: Japan PIII
(Oct.4.2017)

Takeda Pharmaceutical said on October 3 that its once-daily oral gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix (development code: TAK-385) showed non-inferiority to leuprorelin acetate in a PIII clinical study in Japanese women with uterine fibroids ...
(LOG IN FOR FULL STORY)

News Calendar